← Leaderboards
Milan Tomic
Xoma Corporation
$64,944,259
Attributed
$64,944,259
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $19.2M · FY2010–14$20M$15M$10M$5M$0
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$64,944,259 · 3
By mechanism
N01$64,944,259 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseBotulismMonoclonal AntibodiesSupport ContractsProduct DevelopmentManufacturing Process DevelopmentBontoxilysinPreclinical SafetyPreclinical EvaluationSafety TestingSerotypingCell BankDrug FormulationsAdvanced DevelopmentBiodefenseBotulinumPre-ClinicalResearch And DevelopmentToxinTranslational ResearchTherapeutic DevelopmentClostridium Botulinum
Grant awards (7)
BROAD SPECTRUM MONOCLONAL ANTIBODY-BASED THERAPEUTIC FOR BOTULISM$10,911,958
N01 · FY2014 · AI · contact PI
BROAD SPECTRUM MONOCLONAL ANTIBODY-BASED THERAPEUTIC FOR BOTULISM$5,969,753
N01 · FY2013 · AI · contact PI
Monoclonal Antibody-Based Therapeutics for Botulism$15,013,143
N01 · FY2012 · AI · contact PI
Development of Monoclonal Antibody-Based Therapeutics for Botulism$2,157,123
N01 · FY2012 · AI · contact PI
Monoclonal Antibody-Based Therapeutics for Botulism$12,082,342
N01 · FY2011 · AI · contact PI
BROAD SPECTRUM MONOCLONAL ANTIBODY-BASED THERAPEUTIC FOR BOTULISM$7,078,812
N01 · FY2011 · AI · contact PI
Monoclonal Antibody-Based Therapeutics for Botulism$11,731,128
N01 · FY2010 · AI · contact PI